Phathom Pharmaceuticals Ownership | Who Owns Phathom Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Phathom Pharmaceuticals Ownership Summary


Phathom Pharmaceuticals is owned by 88.96% institutional investors, 4.19% insiders, and 6.84% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 17.32% of PHAT shares. Invesco OFI Global Equity is the top mutual fund, with 2.84% of its assets in Phathom Pharmaceuticals shares.

PHAT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPhathom Pharmaceuticals88.96%4.19%6.84%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Frazier life sciences management10.11M17.32%$104.13M
Medicxi ventures management (jersey)7.46M11.55%$60.61M
Jennison associates7.06M10.93%$57.35M
Invesco3.67M5.68%$29.81M
Blackrock funding, inc. /de3.50M5.42%$28.44M
Carlyle group3.50M5.41%$28.39M
Blackrock2.93M5.01%$30.14M
Vanguard group2.78M4.30%$22.57M
Ensign peak advisors2.53M3.91%$20.52M
Nea management company1.96M3.03%$15.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Medicxi ventures management (jersey)7.46M11.46%$60.61M
Catalys pacific1.17M8.18%$9.48M
Propel bio management989.93K7.98%$8.04M
Frazier life sciences management10.11M4.87%$104.13M
Stepstone group lp422.08K3.00%$3.43M
Ghost tree capital600.00K1.94%$6.18M
Avidity partners management lp1.39M1.11%$11.29M
Penn mutual asset management62.80K0.92%$509.95K
Nea management company1.96M0.90%$15.92M
Carlyle group3.50M0.68%$28.39M

Top Buyers

HolderShares% AssetsChange
Wasatch advisors lp1.56M0.06%1.31M
Jennison associates7.06M0.03%1.20M
Morgan stanley762.60K0.00%525.44K
Tang capital management500.00K0.27%500.00K
Gilder gagnon howe1.47M0.19%454.64K

Top Sellers

HolderShares% AssetsChange
Checkpoint capital---2.27M
Portolan capital management---1.70M
Woodline partners lp1.00M0.06%-1.57M
Orbimed advisors---1.45M
Federated hermes---1.40M

New Positions

HolderShares% AssetsChangeValue
Tang capital management500.00K0.27%500.00K$4.06M
Trexquant investment lp378.64K0.04%378.64K$3.07M
Bnp paribas arbitrage, snc39.53K0.00%39.53K$321.00K
Engineers gate manager lp32.50K0.00%32.50K$263.90K
Los angeles capital management21.07K0.00%21.07K$171.09K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-7.00
Srs capital advisors-17.00
Capital performance advisors llp-29.00
Cwm-32.00
Russell investments group-36.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025142-4.05%64,025,009-3.98%880.84%73-22.34%3534.62%
Dec 31, 202458-57.97%26,182,383-63.96%400.32%35-58.82%11-45.00%
Sep 30, 202413818.97%72,638,51228.44%1121.21%8528.79%20-
Jun 30, 2024115-1.71%56,555,1598.24%961.17%6624.53%19-44.12%
Mar 31, 2024117-2.50%52,249,16711.99%911.35%53-28.38%3447.83%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Invesco OFI Global Equity1.98M2.84%-
Invesco Global A1.98M2.83%-
Jennison Health Sciences Equity1.78M2.56%-
Vanguard US Total Market Shares ETF1.65M2.36%280.90K
Vanguard Total Stock Mkt Idx Inv1.59M2.28%-
Jennison SMid Cap Core Equity1.58M2.27%-
Strategic Advisers U.S. Total Stock{mg}1.48M2.16%-273.72K
Wasatch Ultra Growth1.47M2.10%268.48K
Strategic Advisers Small-Mid Cap1.24M1.82%278.88K
PGIM Jennison Small Company A1.21M1.73%-373.30K

Recent Insider Transactions


DateNameRoleActivityValue
May 21, 2025Topper James N-Buy$14.61K
May 14, 2025Topper James N-Buy$20.92K
May 13, 2025Topper James N-Buy$3.54K
May 09, 2025Topper James N-Buy$106.56K
May 12, 2025Topper James N-Buy$38.30K

Insider Transactions Trends


DateBuySell
2025 Q281
2025 Q113
2024 Q422
2024 Q3-3
2024 Q2-1

PHAT Ownership FAQ


Who Owns Phathom Pharmaceuticals?

Phathom Pharmaceuticals shareholders are primarily institutional investors at 88.96%, followed by 4.19% insiders and 6.85% retail investors. The average institutional ownership in Phathom Pharmaceuticals's industry, Biotech Stocks , is 63.96%, which Phathom Pharmaceuticals exceeds.

Who owns the most shares of Phathom Pharmaceuticals?

Phathom Pharmaceuticals’s largest shareholders are Frazier life sciences management (10.11M shares, 17.32%), Medicxi ventures management (jersey) (7.46M shares, 11.55%), and Jennison associates (7.06M shares, 10.93%). Together, they hold 39.80% of Phathom Pharmaceuticals’s total shares outstanding.

Does Blackrock own Phathom Pharmaceuticals?

Yes, BlackRock owns 5.01% of Phathom Pharmaceuticals, totaling 2.93M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 30.14M$. In the last quarter, BlackRock increased its holdings by 180.99K shares, a 6.59% change.

Who is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Medicxi ventures management (jersey) is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 11.46% of its assets in 7.46M Phathom Pharmaceuticals shares, valued at 60.61M$.

Who is the top mutual fund holder of Phathom Pharmaceuticals shares?

Invesco OFI Global Equity is the top mutual fund holder of Phathom Pharmaceuticals shares, with 2.84% of its total shares outstanding invested in 1.98M Phathom Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools